TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL

被引：0
|
作者：
Ahluwalia, M. S. [1 ,2 ]
Khosla, A. A. [1 ,2 ]
Ozair, A. [1 ]
Kotecha, R. R. [1 ,2 ]
McDermott, M. W. [1 ,2 ]
Mehta, M. P. [1 ,2 ]
Sandoval-Leon, A. C. [1 ]
Mahtani, R. [1 ,2 ]
Peereboom, D. M. [3 ]
机构：
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL 33199 USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
10.1093/neuonc/noad137.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JS06.5.A
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinical efficacy of pyrotinib combined with stereotactic radiosurgery in HER2-positive breast cancer brain metastases.
    Zhen, Junjie
    Bashir, Shoaib
    Yang, Yanying
    Wang, Hui
    Lai, Mingyao
    Cai, Linbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
    Khatri, Vaseem M.
    Mestres-Villanueva, Mariella A.
    Yarlagadda, Sreenija
    Doniparthi, Ajay
    Smith, David B.
    Nakashima, Justyn Y.
    Bryant, John M.
    Zhao, Dekuang
    Upadhyay, Rituraj
    Mills, Matthew N.
    Oliver, Daniel E.
    Yu, Hsiang-Hsuan Michael
    Palmer, Joshua D.
    Williams, Nicole O.
    Mahtani, Reshma L.
    Ahluwalia, Manmeet S.
    Soliman, Hatem H.
    Han, Hyo S.
    Soyano, Aixa E.
    Kim, Youngchul
    Kotecha, Rupesh
    Beyer, Sasha J.
    Ahmed, Kamran A.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [23] Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
    Metro, G.
    Foglietta, J.
    Russillo, M.
    Stocchi, L.
    Vidiri, A.
    Giannarelli, D.
    Crino, L.
    Papaldo, P.
    Mottolese, M.
    Cognetti, F.
    Fabi, A.
    Gori, S.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 625 - 630
  • [24] Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
    Murthy, Rashmi
    Borges, Virginia F.
    Conlin, Alison
    Chaves, Jorge
    Chamberlain, Marc
    Gray, Todd
    Vo, Alex
    Hamilton, Erika
    LANCET ONCOLOGY, 2018, 19 (07): : 880 - 888
  • [25] Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
    Lin, Nancy U.
    Murthy, Rashmi K.
    Abramson, Vandana
    Anders, Carey
    Bachelot, Thomas
    Bedard, Philippe L.
    Borges, Virginia
    Cameron, David
    Carey, Lisa A.
    Chien, A. Jo
    Curigliano, Giuseppe
    DiGiovanna, Michael P.
    Gelmon, Karen
    Hortobagyi, Gabriel
    Hurvitz, Sara A.
    Krop, Ian
    Loi, Sherene
    Loibl, Sibylle
    Mueller, Volkmar
    Oliveira, Mafalda
    Paplomata, Elisavet
    Pegram, Mark
    Slamon, Dennis
    Zelnak, Amelia
    Ramos, Jorge
    Feng, Wentao
    Winer, Eric
    JAMA ONCOLOGY, 2023, 9 (02) : 197 - 205
  • [26] Updated Results of Tucatinib versus Placebo in Combination with Trastuzumab and Capecitabine in Patients with pretreated metastatic HER2-positive Breast Cancer with CNS Metastases (HER2CLIMB)
    Greil, R.
    Lin, U. N.
    Murthy, K. R.
    Abramson, V
    Anders, C.
    Bachelot, T.
    Bedard, L. P.
    Borges, V
    Cameron, D.
    Carey, L.
    Chien, J. A.
    Curigliano, G.
    DiGiovanna, P. M.
    Gelmon, K.
    Hortobagyi, G.
    Hurvitz, S.
    Krop, I
    Loi, S.
    Loibl, S.
    Mueller, V
    Oliveira, M.
    Paplomata, E.
    Pegram, M.
    Slamon, D.
    Zelnak, A.
    Ramos, J.
    Feng, W.
    Winer, E.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (04) : E4 - E5
  • [27] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Mueller, V
    Curigliano, G.
    Borges, V
    Hamilton, E.
    Hurvitz, S.
    Loi, S.
    Murthy, R.
    Okines, A.
    Paplomata, E.
    Cameron, D.
    Carey, L. A.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Ramos, J.
    Feng, W.
    Winer, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 134
  • [28] Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB).
    Curigliano, Giuseppe
    Mueller, Volkmar
    Borges, Virginia F.
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Loi, Sherene
    Murthy, Rashmi Krishna
    Okines, Alicia Frances Clare
    Paplomata, Elisavet
    Cameron, David A.
    Carey, Lisa A.
    Gelmon, Karen A.
    Hortobagyi, Gabriel N.
    Krop, Ian E.
    Loibl, Sibylle
    Pegram, Mark D.
    Slamon, Dennis J.
    Ramos, Jorge
    Zhang, Chiyu
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer (MBC) with brain metastases (BM) (HER2CLIMB)
    Mueller, V
    Lin, N.
    Murthy, R.
    Anders, C.
    Borges, V
    Hurvitz, S.
    Loi, S.
    Abramson, V
    Bedard, P.
    Oliveira, M.
    Zelnak, A.
    Di Giovanna, M.
    Bachelot, T.
    Chien, A. J.
    O'Regan, R.
    Wardley, A.
    Carey, L.
    McGoldrick, S.
    An, X.
    Winer, E. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 161 - 161
  • [30] HER2CLIMB-04: phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)
    Hamilton, Erika
    Carey, Lisa
    Ramos, Jorge
    Chen, Yiyi
    Krop, Ian
    CANCER RESEARCH, 2022, 82 (04)
12345